Board of Directors


Dr Read is the Executive Chairman at Global Kinetics and Venture Partner at Brandon Capital. He is an American serial entrepreneur and venture investor with a track record of building successful companies across the range of life-science technologies. He was previously a managing director of Alloy Ventures and before that had co-founded Affymax NV (acquired by GSK, was the founding investor, Chairman and CEO of Aviron the company that developed FluMist acquired by MedImmune) and Avidia (acquired by Amgen). Leighton has a Bachelor of Science from Rice University and an MD from the University of Texas Health Science Center. He completed internal medicine training at Duke and the Peter Bent Brigham Hospital, where he held appointments at the Harvard Medical School and School of Public Health publishing in the fields of decision and cost-effectiveness analysis. Leighton is currently a director of EBR Systems, Foundry Therapeutics 1 Okogen and Glyscend. He is also a director of BioVentures for Global Health.


Chris is a founding partner of Brandon Capital Partners and Principal Executive of the Medical Research Commercialisation Fund. Chris previously was Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia. He was responsible for the commercialisation of technologies developed at the Baker and the Alfred Hospital, including the management of local and international spinout companies. Prior to this, Chris was the Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. Concurrently during this period, he was an Investment Manager for, and on the investment committee of, Uniseed Pty Ltd, a $60 million pre-seed fund. Chris has international experience with Leiras Pharmaceuticals in Finland, a wholly owned subsidiary of Schering AG, working for their Business Development group. He successfully moved companies to the US, securing investment from US investors for these companies. Past directorships have seen Chris involved directly in the management, fundraising, and successful spinouts of various companies in the life sciences industry. Chris is a Director of BACE Therapeutics P/L, Fibrotech Therapeutics P/L Fluorotrop P/L, Global Kinetics Corporation P/L, Osprey Medical Inc., Polyactiva P/L and Spinifex Pharmaceuticals P/L. Chris has a first-class Honours degree in Science and a Ph.D. in Endocrinology and Physiology from the University of Melbourne. Chris is a member of the Australian Institute of Company Directors and of AusBiotech.


Amanda is the Chief Operating Officer, Investments at BioScience Managers. Amanda is a life science investment professional at BioScience Managers where she plays a key role in deal origination, prospective investment due diligence, deal negotiation and portfolio management. Prior to BioScience Managers, Amanda was a Postdoctoral Fellow at Columbia University in New York City investigating molecular processes involved in intracellular trafficking. Amanda is currently a Director of SummatiX Pty Ltd, Rex Bionics Pty Ltd, Global Kinetics Corporation and a Board Observer for Canary Medical and Saluda Medical Pty Ltd. Amanda has a first class honours degree in Science and a PhD in Biochemistry from La Trobe University. She also has an MBA from Melbourne Business School.


Greg Barrett became a member of our board of directors in March 2019. He has more than 35 years of medical device experience, working primarily in the fields of gastroenterology, urology, cardiology, gynecology and minimally invasive surgery. He was previously president and CEO at DFINE Inc, where he restructured the company and negotiated its sale to Merit Medical. Prior to DFINE, Greg was Chairman, President, and CEO of BÂRRX Medical, which was sold to Covidien in January 2012. Previous to joining BÂRRX Medical, Greg served as President and CEO of ACMI Corporation, which was acquired by Gyrus Medical and subsequently by Olympus Medical. Prior to ACMI, he was Group Vice President at Boston Scientific Corporation; Vice President, Global Sales and Marketing at both Orthofix Corporation (formerly American Medical Electronics) and Baxter Healthcare. Greg holds a B.A. in Marketing from the University of Texas.


Matthew C. Garrett has served as iRhythm’s Chief Financial Officer since January 2013. Previously, he served as Chief Financial Officer of Navigenics, Inc., a provider of genetic testing for common health conditions. Prior to that, he served as Director of Business Development at Corventis Inc., a health monitor applications company and he also served as Vice President of Finance, Chief Accounting Officer and Treasurer for Cogentus Pharmaceuticals Inc., a developer of prescription pharmaceutical products. Before that, Mr. Garrett served as Finance Director in Research & Development and Director of Strategic Marketing and Pricing at Affymetrix, Inc. Earlier in his career, he held various finance roles at Guidant Corporation, a medical technology company focused on cardiac and vascular solutions. Mr. Garrett has a B.A. in Finance from the University of Iowa, Iowa City and an M.B.A. from the Kelley School of Business, Indiana University Bloomington.